Jagsonpal [JAGSNPHARM] vs GPT Healthcare [GPTHEALTH] Detailed Stock Comparison
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Jagsonpal Pharmaceuticals Ltd. wins in 11 metrics, GPT Healthcare Ltd. wins in 9 metrics, with 0 ties. Jagsonpal Pharmaceuticals Ltd. appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Jagsonpal Pharmaceuticals Ltd. | GPT Healthcare Ltd. | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 33.34 | 27.54 | GPT Healthcare Ltd. |
| Price-to-Book Ratio | 5.34 | 4.41 | GPT Healthcare Ltd. |
| Debt-to-Equity Ratio | 3.50 | 38.28 | Jagsonpal Pharmaceuticals Ltd. |
| PEG Ratio | -0.51 | -1.17 | Jagsonpal Pharmaceuticals Ltd. |
| EV/EBITDA | 20.20 | 17.00 | GPT Healthcare Ltd. |
| Profit Margin (TTM) | 14.53% | 9.06% | Jagsonpal Pharmaceuticals Ltd. |
| Operating Margin (TTM) | 19.03% | 11.32% | Jagsonpal Pharmaceuticals Ltd. |
| EBITDA Margin (TTM) | 19.03% | 11.32% | Jagsonpal Pharmaceuticals Ltd. |
| Return on Equity | 23.07% | 20.14% | Jagsonpal Pharmaceuticals Ltd. |
| Return on Assets (TTM) | 19.90% | 12.99% | Jagsonpal Pharmaceuticals Ltd. |
| Free Cash Flow (TTM) | $549.52M | $174.71M | Jagsonpal Pharmaceuticals Ltd. |
| Dividend Yield | 1.01% | 2.44% | GPT Healthcare Ltd. |
| 1-Year Return | -9.26% | -1.29% | GPT Healthcare Ltd. |
| Price-to-Sales Ratio (TTM) | 4.83 | 2.49 | GPT Healthcare Ltd. |
| Enterprise Value | $11.62B | $11.77B | GPT Healthcare Ltd. |
| EV/Revenue Ratio | 4.13 | 2.63 | GPT Healthcare Ltd. |
| Gross Profit Margin (TTM) | 63.74% | 62.58% | Jagsonpal Pharmaceuticals Ltd. |
| Revenue per Share (TTM) | $42 | $55 | GPT Healthcare Ltd. |
| Earnings per Share (Diluted) | $6.06 | $4.94 | Jagsonpal Pharmaceuticals Ltd. |
| Beta (Stock Volatility) | -0.47 | 0.08 | Jagsonpal Pharmaceuticals Ltd. |
Jagsonpal Pharmaceuticals Ltd. vs GPT Healthcare Ltd. Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd. | 0.81% | 7.29% | 3.34% | 15.99% | 6.64% | 10.68% |
| GPT Healthcare Ltd. | -0.63% | 0.03% | 4.02% | 19.68% | 4.37% | 5.03% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Jagsonpal Pharmaceuticals Ltd. | -9.26% | 40.83% | 241.72% | 1,222.84% | 3,458.75% | 2,535.79% |
| GPT Healthcare Ltd. | -1.29% | -22.71% | -22.71% | -22.71% | -22.71% | -22.71% |
Performance & Financial Health Analysis: Jagsonpal Pharmaceuticals Ltd. vs GPT Healthcare Ltd.
| Metric | JAGSNPHARM | GPTHEALTH |
|---|---|---|
| Market Information | ||
| Market Cap | ₹13.59B | ₹11.02B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 263,853 | 90,831 |
| 90 Day Avg. Volume | 325,105 | 169,613 |
| Last Close | ₹213.10 | ₹147.24 |
| 52 Week Range | ₹155.00 - ₹301.65 | ₹115.00 - ₹185.00 |
| % from 52W High | -29.36% | -20.41% |
| All-Time High | ₹328.04 (Nov 25, 2024) | ₹219.90 (Feb 26, 2024) |
| % from All-Time High | -35.04% | -33.04% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.02% | 0.18% |
| Quarterly Earnings Growth | -0.66% | -0.24% |
| Financial Health | ||
| Profit Margin (TTM) | 0.15% | 0.09% |
| Operating Margin (TTM) | 0.19% | 0.11% |
| Return on Equity (TTM) | 0.23% | 0.20% |
| Debt to Equity (MRQ) | 3.50 | 38.28 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹37.80 | ₹30.88 |
| Cash per Share (MRQ) | ₹24.28 | ₹4.08 |
| Operating Cash Flow (TTM) | ₹532.93M | ₹631.61M |
| Levered Free Cash Flow (TTM) | ₹553.61M | ₹499.22M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.01% | 2.44% |
| Last 12-Month Dividend | ₹2.50 | ₹3.50 |
Valuation & Enterprise Metrics Analysis: Jagsonpal Pharmaceuticals Ltd. vs GPT Healthcare Ltd.
| Metric | JAGSNPHARM (Apr 24, 2026) | GPTHEALTH (Apr 24, 2026) |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 33.34 | 27.54 |
| Forward P/E | N/A | 17.67 |
| PEG Ratio | -0.51 | -1.17 |
| Price to Sales (TTM) | 4.83 | 2.49 |
| Price to Book (MRQ) | 5.34 | 4.41 |
| Market Capitalization | ||
| Market Capitalization | ₹13.59B | ₹11.02B |
| Enterprise Value | ₹11.62B | ₹11.77B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.13 | 2.63 |
| Enterprise to EBITDA | 20.20 | 17.00 |
| Risk & Other Metrics | ||
| Beta | -0.47 | 0.08 |
| Book Value per Share (MRQ) | ₹37.80 | ₹30.88 |
Financial Statements Comparison: Jagsonpal Pharmaceuticals Ltd. vs GPT Healthcare Ltd.
Financial Metrics
Loading Financial Charts...
Revenue
Operating Margin
Profit Margin
Long Term Debt
Income Flow Analysis
Financial Statements Comparison
Income Statement
| Metric | JAGSNPHARM (2025) | GPTHEALTH (2025) |
|---|---|---|
| Revenue/Sales | 2.69B | 4.06B |
| Cost of Goods Sold | 966.68M | 1.47B |
| COGS % of Revenue | 36.0% | 36.2% |
| Gross Profit | 1.72B | 2.59B |
| Gross Margin | 64.0% | 63.8% |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | 429.40M | 671.21M |
| Operating Margin | 16.0% | 16.5% |
| EBITDA | 591.61M | 927.08M |
| EBITDA Margin | 22.0% | 22.8% |
| Pre-Tax Income | 698.59M | 693.46M |
| Pre-Tax Income % of Revenue | 26.0% | 17.1% |
| Income Tax | 144.98M | 194.24M |
| Income Tax % of Revenue | 5.4% | 4.8% |
| Net Income (Profit) | 553.61M | 499.22M |
| Profit Margin | 20.6% | 12.3% |
Balance Sheet & Liquidity Metrics
| Metric | JAGSNPHARM (2025) | GPTHEALTH (2025) |
|---|---|---|
| Cash & Equivalents | 112.15M | 16.59M |
| Total Current Assets | 1.61B | 788.16M |
| Total Current Assets % of Revenue | 60.0% | 19.4% |
| Total Current Liabilities | 259.04M | 742.43M |
| Total Current Liabilities % of Revenue | 9.6% | 18.3% |
| Long-Term Debt | 76.32M | 227.25M |
| Long-Term Debt % of Revenue | 2.8% | 5.6% |
| Total Shareholders Equity | 2.40B | 2.48B |
| Retained Earnings | 1.49B | 887.46M |
| Retained Earnings % of Revenue | 55.4% | 21.8% |
| Property, Plant & Equipment | 82.26M | 2.27B |
Cash Flow Statement Comparison
| Metric | JAGSNPHARM (2025) | GPTHEALTH (2025) |
|---|---|---|
| Operating Cash Flow | 532.93M | 631.61M |
| Operating Cash Flow % of Revenue | 19.8% | 15.5% |
| Capital Expenditures | 353.70M | -494.37M |
| Free Cash Flow | 549.52M | 174.71M |
| FCF Margin | 20.4% | 4.3% |
| Debt Repayment | N/A | -87.55M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | JAGSNPHARM | GPTHEALTH |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Shares Outstanding | 67.14M | 82.05M |
| Float Shares | 16.16M | 26.97M |
| % Held by Insiders | 75.35% | 65.57% |
| % Held by Institutions | 2.69% | 7.45% |
| % Held by Public | 21.96% | 26.98% |
Dividend Analysis & Yield Comparison: Jagsonpal Pharmaceuticals Ltd. vs GPT Healthcare Ltd.
| Metric | JAGSNPHARM | GPTHEALTH |
|---|---|---|
| Last 12-Month Dividend | ₹2.50 | ₹3.50 |
| Last 12-Month Dividend Yield | 1.01% | 2.44% |
| 3-Year Avg Annual Dividend | ₹1.37 | ₹2.00 |
| 3-Year Avg Dividend Yield | 0.66% | 0.70% |
| 3-Year Total Dividends | ₹4.10 | ₹6.00 |
| Ex-Dividend Date | Sep 12, 2025 | Nov 14, 2025 |